Literature DB >> 19194468

Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase.

Y Luo, X-Y Lai, Y-M Tan, J-M Shi, Y-M Zhao, X-Y Han, G-F Zheng, X-L Zhu, J Sun, Y-L Zheng, G-Q Wu, J-S He, S-Y Chen, A-Y Jin, W-Z Xie, X-J Ye, Z Cai, M-F Lin, H Huang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19194468     DOI： 10.1038/leu.2008.401

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Moxa-stick suffumigation for disinfecting air in hematology and hematopoietic stem cell transplantation wards with class 100 laminar flow.

Authors:  Jing-song He; Qing Yang; Wei-jia Huang; Xiao-rong Hu
Journal:  Chin J Integr Med       Date:  2012-12-21       Impact factor: 1.978

Review 2.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

Review 3.  Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.

Authors:  Nitin Jain; Koen van Besien
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

Review 4.  The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

Authors:  A John Barrett; Sawa Ito
Journal:  Blood       Date:  2015-04-07       Impact factor: 22.113

5.  Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Bing Hao; Song Gao; Yi-Wen Sang; Lin Wang; Xue-Qin Meng; Jing-Ya You
Journal:  J Zhejiang Univ Sci B       Date:  2019 Oct.       Impact factor: 3.066

Review 6.  Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.

Authors:  Uday Deotare; Dennis Dong Hwan Kim; Jeffrey H Lipton
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

Review 7.  Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.

Authors:  S R Pingali; R E Champlin
Journal:  Bone Marrow Transplant       Date:  2015-05-18       Impact factor: 5.483

Review 8.  Allogeneic transplantation for CML in the TKI era: striking the right balance.

Authors:  Andrew J Innes; Dragana Milojkovic; Jane F Apperley
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

9.  Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.

Authors:  Houli Zhao; Jieping Wei; Guoqing Wei; Yi Luo; Jimin Shi; Qu Cui; Mingfeng Zhao; Aibin Liang; Qing Zhang; Jianmin Yang; Xin Li; Jing Chen; Xianmin Song; Hongmei Jing; Yuhua Li; Siguo Hao; Wenjun Wu; Yamin Tan; Jian Yu; Yanmin Zhao; Xiaoyu Lai; Elaine Tan Su Yin; Yunxiong Wei; Ping Li; Jing Huang; Tao Wang; Didier Blaise; Lei Xiao; Alex H Chang; Arnon Nagler; Mohamad Mohty; He Huang; Yongxian Hu
Journal:  J Hematol Oncol       Date:  2020-05-04       Impact factor: 17.388

10.  Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation.

Authors:  Håkon Reikvam; Jørn Skavland; Stein-Erik Gullaksen; Randi Hovland; Tobias Gedde-Dahl; Øystein Bruserud; Bjørn Tore Gjertsen
Journal:  Case Rep Hematol       Date:  2018-09-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.